Immutep, page-43

For those that wonder my continued postings of keytruda.......

Merck was the highest performer on the Dow Jones index last year

and that performance was on the back of keytruda, according to

market analysts.......

OK, keytruda is a success, but far from a major success,in that it

helps approx 30/40% conclusively and needs help in the other

40/60% of patients.......

It is apparent to me that Immutep, on the back of Treibels advice

have decided to piggy back on keytruda,, initially in melanoma

in Australia on the back of the PBS scheme......i:e, nothing to do 

with Merck.......

This is where it gets interesting, Merck in their wisdom have decided

to collaborate with Immutep in USA trials at a at market cost of  

$150,000 per annum per patient on a supply only agreement in

trials controlled by Immutep (very important IMO).....

If Keytruda expansion programmes can be assisted by EFTI 

we are in the money...

Hence my interest in keytruda....